This story summarizes results from a new Dutch study that finds women undergoing screening mammography reduce their risk of dying from breast cancer by 49%. The article does a good job of briefly summarizing some of the debate around the age to begin screening and uses an outside expert who identifies some limitations of the study. However, the article fails to ask the hard questions to help readers with a balanced viewpoint.
We’re not sure that women will be any more clear about the state of the evidence after reading this story. There’s been much debate about the benefit of mammography screening and whether the benefits outweigh the harms. This story does not really help women put the information into context, nor does it help them analyze whether this is news that really matters.
There is no discussion of the costs of mammography.
While making an attempt to quantify benefits, the author frames the information in confusing language that appears to indicate cause and effect: “women who underwent screening reduced the risk of dying from breast cancer by 49 percent.” Mammography is screening, not treatment, and does not prevent or cure breast cancer. Citing the conflicting evidence about the benefits of breast cancer screening would improve the quality of the article. For instance, in two large, randomized clinical trials that looked at the benefits of screening mammography for survival, the Malmo and Canadian trials, the women who chose mammography screening had the same breast cancer mortality or death rate as the women who did not.
The article refers briefly to “overtreatment” but fails to explain this or other potential harms.
This article underplayed the limitations of the original study. Crucial details are absent in this article, such as the way in which the women were “invited” into the study (a term used in the original abstract,) how it was determined the women died of breast cancer, what type of cancer was diagnosed, whether or not there was appropriate treatment, and the effects of lead-time bias,where patients do not live longer but know about their cancer longer.
The story should have emphasized that this was a case-control study and should have explained limitations inherent in such a design, making the story’s causality comments inappropriate.
A statistical reference to the number of women who are diagnosed and die from breast cancer would be useful, but there is no direct evidence of disease-mongering.
Although there is no specific indication of whether or not there is a conflict of interest ,the article is considered satisfactory because it names the source of the study and provides one independent source, Dr. Stephanie Burnik.
There is no discussion of alternatives to “routine mammograms” although the article does mention the debate as to the best schedule and age to begin. The clear alternative is not to be screened.
Not applicable. The study was in the Netherlands, which has a national screening program.
Screening mammography is not a new approach to detecting breast cancer.
This article clearly states it is based on a publication in the journal Cancer Epidemiology, Biomarkers and Prevention Dec. 6,2011.
Systematic, Criteria-Driven
Take all the issues enmeshed in any cancer screening story and amplify it with the liquid biopsy issue. @AP's @CarlaKJohnson. did a solid job here. https://apnews.com/article/science-business-health-hodgkin-lymphoma-oregon-ca899bb9c4c7f1859d4e9ce16a1cf78d
Come on, NY Times; you must do better than this. Important research doesn’t need hype and the “breaking news” BS doesn’t help readers or patients. https://www.healthnewsreview.org/2022/03/nyt-proclaims-breaking-news/
Comments (1)
Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.
nancynursez637
December 11, 2011 at 6:28 pmThe literature is all over the place on whether screening is advantageous and at what age. To not screen, embraces a philosophy of “acceptable losses”. those we don’t find in time will just die, but we will have saved a pile of money with reducint screening.
Our Comments Policy
But before leaving a comment, please review these notes about our policy.
You are responsible for any comments you leave on this site.
This site is primarily a forum for discussion about the quality (or lack thereof) in journalism or other media messages (advertising, marketing, public relations, medical journals, etc.) It is not intended to be a forum for definitive discussions about medicine or science.
We will delete comments that include personal attacks, unfounded allegations, unverified claims, product pitches, profanity or any from anyone who does not list a full name and a functioning email address. We will also end any thread of repetitive comments. We don”t give medical advice so we won”t respond to questions asking for it.
We don”t have sufficient staffing to contact each commenter who left such a message. If you have a question about why your comment was edited or removed, you can email us at feedback@healthnewsreview.org.
There has been a recent burst of attention to troubles with many comments left on science and science news/communication websites. Read “Online science comments: trolls, trash and treasure.”
The authors of the Retraction Watch comments policy urge commenters:
We”re also concerned about anonymous comments. We ask that all commenters leave their full name and provide an actual email address in case we feel we need to contact them. We may delete any comment left by someone who does not leave their name and a legitimate email address.
And, as noted, product pitches of any sort – pushing treatments, tests, products, procedures, physicians, medical centers, books, websites – are likely to be deleted. We don”t accept advertising on this site and are not going to give it away free.
The ability to leave comments expires after a certain period of time. So you may find that you’re unable to leave a comment on an article that is more than a few months old.
You might also like